AI Engines For more Details: Perplexity Kagi Labs You
Lowering Blood Pressure: Bisoprolol works by blocking the action of certain natural chemicals in the body, such as adrenaline, which helps to reduce the heart rate and relax blood vessels. This results in lower blood pressure, which can help to reduce the risk of heart attacks, strokes, and kidney problems associated with high blood pressure.
Management of Heart Conditions: Bisoprolol is used in the management of various heart conditions, including angina (chest pain) and heart failure. By reducing the workload on the heart and improving its efficiency, bisoprolol can help to relieve symptoms such as chest pain, shortness of breath, and fatigue in patients with these conditions.
Heart Rate Regulation: Bisoprolol helps to regulate the heart rate by slowing down the heart's pumping action. This can be beneficial for individuals with irregular heart rhythms (arrhythmias) or those at risk of developing them.
Improvement of Exercise Tolerance: In patients with heart failure, bisoprolol can improve exercise tolerance and quality of life by reducing symptoms such as shortness of breath and fatigue.
Reduction of Mortality: Bisoprolol has been shown to reduce the risk of mortality and hospitalizations in patients with heart failure, making it an important medication for the long-term management of this condition.
Side Effects: Like all medications, bisoprolol fumarate can cause side effects. Common side effects may include fatigue, dizziness, weakness, headache, cold hands, and feet. These side effects are usually mild and transient, but they may require adjustment of the medication dosage or discontinuation in some cases.
Blood Sugar Regulation: Beta-blockers like bisoprolol may affect blood sugar levels, particularly in patients with diabetes. It's essential for diabetic patients taking bisoprolol to monitor their blood sugar levels closely and to discuss any changes with their healthcare provider.
Asthma and Breathing Problems: Bisoprolol may exacerbate breathing problems in patients with asthma, chronic obstructive pulmonary disease (COPD), or other respiratory conditions. It is generally not recommended for use in individuals with severe asthma or COPD.
Abrupt Withdrawal: Abrupt discontinuation of bisoprolol therapy can lead to rebound hypertension, worsening of angina symptoms, or exacerbation of heart failure. Therefore, it's important to gradually taper the dosage under medical supervision if the medication needs to be stopped.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0 | 0.1 | 0 |
Allergies | 0.1 | 0 | 0 |
Allergy to milk products | 0.1 | 0 | 0 |
Alzheimer's disease | 0 | 0 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | 0 |
Ankylosing spondylitis | 0.1 | 0.1 | |
Anorexia Nervosa | 0 | 0 | 0 |
Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
Asthma | 0.1 | 0 | 0 |
Atherosclerosis | 0 | 0 | 0 |
Atrial fibrillation | 0 | 0 | 0 |
Autism | 0.5 | 0.6 | -0.2 |
Autoimmune Disease | 0 | 0 | 0 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0 | 0 | |
Biofilm | 0.1 | 0.1 | |
Bipolar Disorder | 0 | 0 | |
Brain Trauma | 0 | 0 | |
Breast Cancer | 0 | 0 | |
Cancer (General) | 0.6 | -0.6 | |
Carcinoma | 0 | 0 | |
Celiac Disease | 0.5 | 0.5 | |
Cerebral Palsy | 0 | 0 | |
Chronic Fatigue Syndrome | 0.3 | 0.5 | -0.67 |
Chronic Kidney Disease | 0 | 0 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0 | 0 |
Chronic Urticaria (Hives) | 0.1 | 0.1 | |
Coagulation / Micro clot triggering bacteria | 0.1 | 0 | 0 |
Cognitive Function | 0 | 0 | 0 |
Colorectal Cancer | 0.8 | 0.3 | 1.67 |
Constipation | 0.5 | 0.5 | |
Coronary artery disease | 0.1 | 0.1 | |
COVID-19 | 0.6 | 0.5 | 0.2 |
Crohn's Disease | 0.6 | 0.6 | |
Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
cystic fibrosis | 0.1 | 0.1 | |
d-lactic acidosis (one form of brain fog) | 0 | 0 | |
deep vein thrombosis | 0.1 | 0 | 0 |
Denture Wearers Oral Shifts | 0 | 0 | |
Depression | 1.1 | 0.6 | 0.83 |
Dermatomyositis | 0 | 0 | |
Eczema | 0 | 0 | 0 |
Endometriosis | 0.1 | 0 | 0 |
Eosinophilic Esophagitis | 0 | 0 | |
Epilepsy | 0.1 | 0.1 | |
erectile dysfunction | 0 | 0 | |
Fibromyalgia | 0 | 0 | 0 |
Functional constipation / chronic idiopathic constipation | 0.6 | 0 | 0 |
gallstone disease (gsd) | 0.1 | 0.1 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0 | 0 |
Generalized anxiety disorder | 0.1 | 0 | 0 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0 | 0 | |
Gout | 0 | 0 | 0 |
Graves' disease | 0 | 0 | |
Gulf War Syndrome | 0 | 0 | |
Halitosis | 0 | 0 | 0 |
Heart Failure | 0.1 | 0.1 | |
Hidradenitis Suppurativa | 0 | 0 | |
High Histamine/low DAO | 0.1 | 0.1 | |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
hyperglycemia | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 0 | 0 | 0 |
Hypoxia | 0 | 0 | |
IgA nephropathy (IgAN) | 0 | 0 | 0 |
Inflammatory Bowel Disease | 0.6 | 0.1 | 5 |
Insomnia | 0 | 0 | 0 |
Intelligence | 0.1 | 0.1 | |
Irritable Bowel Syndrome | 0.1 | 0.5 | -4 |
ischemic stroke | 0.1 | 0 | 0 |
Liver Cirrhosis | 0.1 | 0.1 | 0 |
Long COVID | 0.5 | 0.5 | |
Lung Cancer | 0 | 0 | |
Lymphoma | 0 | 0 | |
Mast Cell Issues / mastitis | 0 | 0 | |
ME/CFS with IBS | 0 | 0 | |
ME/CFS without IBS | 0 | 0 | |
membranous nephropathy | 0 | 0 | |
Menopause | 0 | 0 | |
Metabolic Syndrome | 0.1 | 0.5 | -4 |
Mood Disorders | 0.6 | 0.6 | 0 |
multiple chemical sensitivity [MCS] | 0 | 0 | |
Multiple Sclerosis | 0.6 | 0 | 0 |
myasthenia gravis | 0 | 0 | 0 |
Neuropathy (all types) | 0 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.1 | |
Obesity | 0.1 | 0.6 | -5 |
obsessive-compulsive disorder | 0.6 | 0 | 0 |
Osteoarthritis | 0 | 0 | 0 |
Osteoporosis | 0 | 0 | 0 |
pancreatic cancer | 0 | 0 | 0 |
Parkinson's Disease | 0.1 | 0 | 0 |
Polycystic ovary syndrome | 0.5 | 0 | 0 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
primary biliary cholangitis | 0 | 0 | 0 |
Primary sclerosing cholangitis | 0 | 0 | 0 |
Psoriasis | 0.1 | 0.1 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0 | 0 | 0 |
Rosacea | 0 | 0 | |
Schizophrenia | 0 | 0 | 0 |
scoliosis | 0 | 0 | |
Sjögren syndrome | 0 | 0 | |
Slow gastric motility / Gastroparesis | 0 | 0 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
Stress / posttraumatic stress disorder | 0.1 | 0.1 | |
Systemic Lupus Erythematosus | 0 | 0 | |
Tic Disorder | 0.5 | 0.5 | |
Tourette syndrome | 0 | 0 | |
Type 1 Diabetes | 0.5 | 0.5 | 0 |
Type 2 Diabetes | 0.8 | 0.8 | 0 |
Ulcerative colitis | 0.8 | 0.5 | 0.6 |
Unhealthy Ageing | 0.5 | 0.5 | |
Vitiligo | 0 | 0 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]